Skip to content

House Calls and Peer Mentorship

Comparing the Effectiveness of House Calls and Peer Mentorship to Reduce Racial Disparities in Live Donor Kidney Transplantation

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03354910
Acronym
HC+PM
Enrollment
320
Registered
2017-11-28
Start date
2018-04-30
Completion date
2022-12-18
Last updated
2024-03-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic Kidney Disease, End-Stage Renal Disease

Keywords

Live Donor Kidney Transplantation, LDKT, Disparity, African American, Education, Patient Support

Brief summary

Live donor kidney transplantation (LDKT) offers the most optimal survival and quality of life benefit for those with late-stage chronic kidney disease. However, minorities, especially blacks, are much less likely to receive LDKT than whites. Given the shortage of deceased donor organs, interventions expanding access to LDKT are needed, particularly for minority patients. House Calls (HC), an educational intervention developed by this study's PI has been shown to be an effective program for raising rates of live donation, especially for black patients. While the HC program has shown outstanding results, participant feedback suggested that follow-up may provide even more benefits. Previous research suggests that peer mentorship (PM) from former or current patients with ESRD may be effective in raising rates of living donation. As such, peer mentorship programs may act as an effective follow-up for HC participants. This study will examine the impact of the HC intervention combined with the peer mentorship program of the National Kidney Foundation on rates of live donor kidney transplantation.

Interventions

BEHAVIORALHouse Call

60 to 90 minute home based educational intervention which will be administered by a health educator.

BEHAVIORALPeer Mentorship

A National Kidney Foundation Peer Mentor will be assigned to the participant to provide contact and support to study participants.

Sponsors

Medical University of South Carolina
CollaboratorOTHER
Patient-Centered Outcomes Research Institute
CollaboratorOTHER
Beth Israel Deaconess Medical Center
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
HEALTH_SERVICES_RESEARCH
Masking
DOUBLE (Investigator, Outcomes Assessor)

Intervention model description

Treatment assignments will be based on a computer-generated randomization scheme, stratified by age (\<60 vs. ≥60 yrs old) and household income (\<250% vs. ≥250% of federal poverty guidelines), since older and low-income patients are known to have lower LDKT rates a priori. Patients will be randomized into one of three treatment arms in a 1:3:3 fashion such that 54 Usual Care, 160 HC and 160 HC+PM patients will be enrolled. The study investigators and research assistants conducting the study assessments of patients will remain blinded to the treatment assignments. KT candidates will be informed of group assignment immediately after completing the Baseline assessment.

Eligibility

Sex/Gender
ALL
Age
21 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Black race (including possible Cape Verdean, Haitian, Dominican) * ≥18 yrs old * English speaking * Meets eligibility criteria for kidney transplant evaluation * Ability to provide informed consent * Resides within 1.5 hr drive of HC educator

Exclusion criteria

* Temporarily Unavailable (TU) on the waiting list and TU is likely to exceed 6 months based on judgement of kidney transplant team * Awaiting combined kidney-liver transplantation * Awaiting simultaneous pancreas-kidney transplantation * Participation in another study to increase the likelihood of LDKT * Prior participation in a transplant HC * Prior or current participation in the NKF PM program

Design outcomes

Primary

MeasureTime frameDescription
Live donor kidney transplants1 Year Post-InterventionThe primary outcome for this study is the proportion of enrolled patients with live donor kidney transplants after 1 year.

Secondary

MeasureTime frameDescription
Live donor evaluations1 Year Post-InterventionA secondary outcome for the study is the proportion of enrolled patients with a live donor evaluation at the one-year endpoint. A live donor evaluation is defined as the completion of a transplant evaluation to determine whether a potential living donor is eligible to donate.
Live donor inquiries1 Year Post-InterventionA secondary outcome for the study is proportion of enrolled patients with live donor inquiries at the one-year endpoint. A live donor inquiry is when an individual contacts the transplant center to express interest in living donation, regardless of when they complete the entire live donor evaluation.

Other

MeasureTime frameDescription
Reduced live donor kidney transplant concerns measured through measured Living Donation Kidney Transplant Concerns scale (LDKT-C) scoreBaseline, 1 Week Post-Intervention, 6 Weeks Post-Intervention, and 12 Weeks Post-InterventionPatient's concerns towards LDKT is measured using a 5-point scale, the Living Donation Kidney Transplant Concerns scale (LDKT-C) where patients indicate their level of concern towards common concerns patients have regarding living donation. A higher score on this assessment indicates higher levels of concern towards living donation.
Improvement in live donor kidney transplant knowledge measured through Living Donation Kidney Transplant Knowledge (LDKT-K) scale scoreBaseline, 1 Week Post-Intervention, 6 Weeks Post-Intervention, and 12 Weeks Post-InterventionAn improvement in patient knowledge is measured by the change in score of a scored instrument, the Living Donation Kidney Transplant Knowledge Scale (LDKT-K). The LDKT-K is a scored true or false questionnaire that tests patient's knowledge on living donation. A higher score indicates that a participant answered more questions correctly.
Improvement in self-efficacy discussing LDKT measured through Living Donation Kidney Transplant Self-Efficacy scale (LDKT-SE) scoreBaseline, 1 Week Post-Intervention, 6 Weeks Post-Intervention, and 12 Weeks Post-InterventionPatient's self-efficacy towards doing activities to pursue LDKT (e.g. willingness and confidence to approach others for donation, following-up with potential donors) is measured through a self-report instrument, the Living Donation Kidney Transplant Self-Efficacy (LDKT-SE) scale. A higher score on this assessment indicates higher self-efficacy for patients pursuing LDKT.
Greater amount of time spent discussing LDKT and higher quality interactions measured through the Talking About Living Donation (TaLKeD) instrumentBaseline, 1 Week Post-Intervention, 6 Weeks Post-Intervention, and 12 Weeks Post-InterventionThe time patients speak with others about LDKT and whether these interactions are of higher quality compared to pre-intervention is measured through a self-report instrument, Talking About Living Donation (TaLKeD), that asks the cumulative time patient's spoke with others (family, friends, etc.) about living donation and their perceived quality of these interactions (poor, fair, good, very good, excellent).
Improvement in live donor kidney transplant readiness measured through Living Donation Kidney Transplant Readiness scale (LDKT-R) scoreBaseline, 1 Week Post-Intervention, 6 Weeks Post-Intervention, and 12 Weeks Post-InterventionImprovement in patient readiness to pursue LDKT is measured by a scored instrument, the Living Donation Kidney Transplant Readiness Scale (LDKT-R). The LDKT-R is a 5-point scale where patient's self report their readiness to pursue living donation and where in the process they are (i.e., they are beginning to think about living donation, have spoken with potential donors, etc.) A higher score on this assessment indicates greater readiness to pursue LDKT.
Reduced health care mistrust measured through Health Care Distrust Scale (HCDS) scoreBaseline, 1 Week Post-Intervention, 6 Weeks Post-Intervention, and 12 Weeks Post-InterventionReduction in patient mistrust towards the health care system is measured through a scale, the Health Care Distrust Scale (HCDS). This scale is a 5-point Likert scale that measures the degree of agreement patients have on statements regarding their trust of the medical system. For example, one such statement reads the health care systems lie to make money. A higher score on this assessment indicates higher levels of mistrust of the health care system.

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026